National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Rheumatology (Oxford). 2022 Aug 3;61(8):3149-3160. doi: 10.1093/rheumatology/keab868.
Discovery of the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome demonstrates that somatic mutations in haematological precursor cells can cause adult-onset, complex inflammatory disease. Unlike germline mutations, somatic mutations occur throughout the lifespan, are restricted to specific tissue types, and may play a causal role in non-heritable rheumatological diseases, especially conditions that start in later life. Improvements in sequencing technology have enabled researchers and clinicians to detect somatic mutations in various tissue types, especially blood. Understanding the relationships between cell-specific acquired mutations and inflammation is likely to yield key insights into causal factors that underlie many rheumatological diseases. The objective of this review is to detail how somatic mutations are likely to be relevant to clinicians who care for patients with rheumatological diseases, with particular focus on the pathogenetic mechanisms of the VEXAS syndrome.
VEXAS(空泡、E1 酶、X 连锁、自身炎症、体细胞)综合征的发现表明,造血前体细胞中的体细胞突变可导致成人发病的、复杂的炎症性疾病。与种系突变不同,体细胞突变发生在整个生命周期中,仅局限于特定的组织类型,并且可能在非遗传性风湿病中发挥因果作用,尤其是在生命后期发病的疾病。测序技术的改进使研究人员和临床医生能够在各种组织类型中检测体细胞突变,尤其是血液。了解特定细胞获得性突变与炎症之间的关系,可能会深入了解许多风湿病的因果因素。本综述的目的是详细说明体细胞突变如何与治疗风湿病患者的临床医生相关,特别关注 VEXAS 综合征的发病机制。